An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.

Virology Journal
Guangyu ZhaoYusen Zhou

Abstract

A 2009 global influenza pandemic caused by a novel swine-origin H1N1 influenza A virus has posted an increasing threat of a potential pandemic by the highly pathogenic avian influenza (HPAI) H5N1 virus, driving us to develop an influenza vaccine which confers cross-protection against both H5N1 and H1N1 viruses. Previously, we have shown that a tetra-branched multiple antigenic peptide (MAP) vaccine based on the extracellular domain of M2 protein (M2e) from H5N1 virus (H5N1-M2e-MAP) induced strong immune responses and cross-protection against different clades of HPAI H5N1 viruses. In this report, we investigated whether such M2e-MAP presenting the H5N1-M2e consensus sequence can afford heterosubtypic protection from lethal challenge with the pandemic 2009 H1N1 virus. Our results demonstrated that H5N1-M2e-MAP plus Freund's or aluminum adjuvant induced strong cross-reactive IgG antibody responses against M2e of the pandemic H1N1 virus which contains one amino acid variation with M2e of H5N1 at position 13. These cross-reactive antibodies may maintain for 6 months and bounced back quickly to the previous high level after the 2nd boost administered 2 weeks before virus challenge. H5N1-M2e-MAP could afford heterosubtypic protection ...Continue Reading

References

Aug 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·J P Tam
Apr 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Andrea JegerlehnerMartin F Bachmann
Feb 5, 2008·Vaccine·Dubravka Grdic EliassonNils Lycke
Feb 7, 2008·The Journal of Biological Chemistry·Marina De FiletteXavier Saelens
Apr 8, 2009·Expert Review of Vaccines·Michael SchotsaertXavier Saelens
Nov 7, 2009·AACN Advanced Critical Care·Nancy BlakeDawn England
Jan 19, 2010·Microbes and Infection·Lanying DuShibo Jiang

❮ Previous
Next ❯

Citations

Jun 8, 2011·Immunology and Cell Biology·Garry W LynchJohn S Sullivan
Sep 24, 2011·Trends in Immunology·Kaval KaurPatrick C Wilson
Dec 23, 2014·Microbes and Infection·Naru ZhangLanying Du
Nov 30, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Shihui SunYusen Zhou
Oct 21, 2019·Journal of Biomedical Science·Daria MezhenskayaLarisa Rudenko

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay
ELISA
light microscopy

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.